AVCO Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (10 Nov 2022 @ 06:00):

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People\'s Republic of China...

Stats
Tagesvolumen	432 165
Durchschnittsvolumen	189 950
Marktkapitalisierung	5.26M
EPS	$-0.120 ( Q1 \| 2024-05-31 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-5.16 (Sector) 43.73 (Industry) 77.35
ATR14	$0.0650 (12.36%)

AIRE 2.70%

ALBT -4.02%

AVCO -16.52%

BPY -0.27%

CHG 0.00%

FLJ 6.50%

INDT 0.01%

LRHC -4.09%

MAYS 0.05%

MDJH -2.38%

OMH 0.18%

QK -3.52%

SFR 0.00%

SFRWW 0.00%

Insider Trading

Date	Person	Action	Amount	type
2021-11-01	Tauzin W J	Buy	8 000	Stock Option (right to buy)
2021-05-01	Tauzin W J	Buy	8 000	Stock Option (right to buy)
2022-05-01	Tauzin W J	Buy	8 000	Stock Option right to buy)
2022-11-01	Tauzin W J	Buy	8 000	Stock Option (right to buy)
2022-01-01	Tauzin W J	Buy	4 000	Stock Option (right to buy)

INSIDER POWER
99.43
Last 93 transactions
Buy: 25 020 963 \| Sell: 11 207 803

Volumen Korrelation

Lang: 0.22 (neutral)

Kurz: 0.78 (moderate)

Signal:(50.974) Neutral

Avalon GloboCare Corp. Korrelation

10 Am meisten positiv korreliert

10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Avalon GloboCare Corp. Korrelation - Währung/Rohstoff

-0.06
( neutral )

0.22
( neutral )

0.00
( neutral )

-0.02
( neutral )

0.18
( neutral )

0.52
( weak )

Avalon GloboCare Corp. Finanzdaten

Annual	2023
Umsatz:	$1.26M
Bruttogewinn:	$202 789 (16.15 %)
EPS:	$-1.590

FY	2023
Umsatz:	$1.26M
Bruttogewinn:	$202 789 (16.15 %)
EPS:	$-1.590

FY	2022
Umsatz:	$1.20M
Bruttogewinn:	$272 728 (22.69 %)
EPS:	$-1.360

FY	2021
Umsatz:	$1.39M
Bruttogewinn:	$414 518 (29.80 %)
EPS:	$-0.110

Financial Reports:

No articles found.

Avalon GloboCare Corp. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Avalon GloboCare Corp.

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People\'s Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing RNA-based FASH-CARTM cell therapy platform. In addition, the company develops avalon clinical-grade tissue-specific exosome (ACTEX); offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Further, it has strategic partnership with the University of Natural Resources and Life Sciences in Vienna and Austria to develop an S-layer vaccine that could be administered by an intranasal or oral route against SARS-CoV-2 and coronavirus that causes COVID-19 disease; and develops Avalon Cell and Avalon Rehab, as well as promotes standardization related to exosome industry. The company is headquartered in Freehold, New Jersey.